References
- Wolff S N. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002; 29: 545–552
- Kurzrock R, Gratwohl A, Paquette M, Wyres M, Okamoto D, Young N. Trilineage responses seen with stem cell factor (stemgen, SCF) and filgastrim (G-CSF) treatment in aplastic anemia (AA) patients. Br J Haematol 1998; 102: 1, (Abstr)
- Schrezenmeier H, Rio B, Camitta B, Paquette R, Socie G, Germing U, et al. A randomized controlled study of ancestim (r-met human Stem Cell Factor, SCF) in newly diagnosed severe or very severe aplastic anemia patients receiving antithymocyte globulin, cyclosporine A and filgastrim. Bone Marrow Transplant 2001; 27: S64
- Grothaus-Pinke B, Gunzelmann S, Fauser A A, Kiehl M G. Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience. Transplantation 2001; 72: 1456–1458
- Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 2004; 103: 725–731